Lung nodule detected by F-18 fluorodeoxyglucose positron emission tomography-computed tomography in patients with papillary thyroid cancer, negative $^{131}$I whole body scan, and undetectable serum-stimulated thyroglobulin levels: two case reports

Chan-Hee Jung¹, Hyeon-Jeong Goong¹, Bo-Yeon Kim¹, Jung-Mi Park², Jeong-Ja Kwak³, Chul-Hee Kim¹, Hyun-Sook Hong⁴, Sung-Koo Kang¹ and Ji-Oh Mok¹,⁵*

Abstract

Introduction: When a pulmonary nodular lesion is detected by F-18 fluorodeoxyglucose positron emission tomography-computed tomography in a patient with post-surgical papillary thyroid carcinoma with undetectable serum-stimulated thyroglobulin levels and negative $^{131}$I whole body scan, diagnosis and management of the nodule may be confusing.

Case presentation: We describe two post-surgical patients with papillary thyroid carcinoma who showed pulmonary nodular lesions detected by F-18 fluorodeoxyglucose positron emission tomography-computed tomography. In both cases serum-stimulated thyroglobulin levels were undetectable and nodular lesions were not detected by $^{131}$I whole body scan. In the first case, a 64-year-old Asian woman showed one focal increased fluorodeoxyglucose uptake lesion in the right lower lobe of one of her lungs. Based on the histologic study, the pulmonary nodular lesion was diagnosed as a solitary pulmonary metastasis from papillary thyroid carcinoma. In the second case, a 59-year-old Asian woman showed a new pulmonary nodule in the right lower lobe. The computed tomography scan of her chest revealed a 9mm nodule in the anterior basal segment and another tiny nodule in the posterior basal segment of the right lower lobe. Six months later, both nodules had increased in size and miliary disseminated nodules were also seen in both lungs. Based on their histology, the pulmonary nodular lesions were considered to be primary lung adenocarcinoma.

Conclusions: The present cases emphasize that physicians should be cautious and make efforts for an accurate diagnosis of pulmonary nodules detected on F-18 fluorodeoxyglucose positron emission tomography-computed tomography in patients with papillary thyroid carcinoma with no evidence of metastasis such as negative $^{131}$I whole body scan and undetectable stimulated serum thyroglobulin levels.

Keywords: F-18 fluorodeoxyglucose positron emission tomography-computed tomography, Papillary thyroid carcinoma, Pulmonary nodule, $^{131}$I whole body scan

* Correspondence: hanna@schmc.ac.kr

¹Department of Internal Medicine, Division of Endocrinology and Metabolism, Soonchunhyang University School of Medicine, Bucheon, Korea

²Division of Endocrinology and Metabolism, Soonchunhyang University School of Medicine, #108 Jung-Dong, Wonmi-Ku, Bucheon, Kyunggi-Do 110-746, Korea

Full list of author information is available at the end of the article

© 2012 Jung et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Introduction**

The detection of a pulmonary nodule in patients who have papillary thyroid carcinoma (PTC) often presents us with a diagnostic dilemma because the lung is one of the most common sites of metastasis of PTC. However, primary lung cancer [1] and benign disease entities, including nonspecific findings, can also coexist with PTC. Radiiodine scans and serum thyroglobulin (Tg) measurements are the most commonly used methods for monitoring patients with thyroid cancer [2]. F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) is primarily used to detect recurrence or metastatic disease in patients who have negative findings with 131I whole body scan (WBS) and elevated Tg levels [3].

Although the clinical value of FDG-PET for the follow up of patients with thyroid cancer remains controversial, its use is rapidly increasing in clinical practice due to concerns about recurrence or metastasis of thyroid cancer. Also, some studies have indicated that FDG-PET is effective in patients with undetectable Tg levels [4,5].

The detection by FDG-PET of a pulmonary nodule in patients with PTC, even those displaying undetectable stimulated Tg and negative 131I WBS, includes a considerable variety of entities, therefore the diagnosis must be made with caution. Although solitary metastasis to the lung from thyroid cancer is quite rare, metastasis from PTC can manifest as a solitary pulmonary nodule. However, clinicians should be aware of the possibility that pulmonary nodules mimicking metastasis on FDG-PET with computed tomography (CT) in patients who have PTC could be primary lung cancer.

We describe two patients who presented with pulmonary nodular lesions by FDG-PET-CT and unexpected results on histologic confirmation with no evidence for distant metastasis on serum-stimulated Tg and 131I WBS.

**Case presentation**

**Case one**

A 64-year-old Asian woman underwent total thyroidectomy and 150mCi 131I therapy due to micro-PTC. The typical radiographic appearance of pulmonary metastases from PTC is a random distribution of multiple nodules [6]. When a solitary nodule is present in patients with post-surgical PTC with undetectable stimulated Tg levels, diagnosis of the nodule is likely to be primary lung cancer, not metastasis to the lung from PTC.

The first presented case represents a rare example of metastasis of PTC presenting as a solitary pulmonary nodule without a clinically suspicious metastasis. The patient initially posed a diagnostic problem because the lung mass was located in a site that was not easily accessible to biopsy. Therefore, we performed surgical resection for accurate diagnosis and treatment under an initial clinical impression of primary lung cancer.

Solitary metastasis to the lung from thyroid cancer is quite rare and 14 cases of a solitary pulmonary metastasis from thyroid cancer, including our case, have been reported [7,8]. Moreover, metastasis from micro-PTC...
has been reported in only five cases, including our case [7]. Seven of the 14 cases initially presented as a solitary lung nodule without a known history of thyroid cancer, with the remainder detected during follow-up for PTC.

In general, serum Tg measurement and radioiodine WBS are recommended for the postoperative follow-up of PTC [2]. However, metastatic diseases for which the ability to take up radioactive iodine is lost are possible. Nakada et al. reported that two of four patients with a solitary pulmonary nodule on multidetector-CT were proven to be metastasis from PTC but neither showed positive radioiodine uptake. Moreover, seven of nine patients (78%) having pulmonary metastasis showed negative radioiodine uptake [9].

CT using iodine-rich contrast material can affect the results of radioiodine WBS. However, we performed a chest CT scan after T4 withdraw of radioiodine WBS in both cases. Therefore, we think that the results of WBS were not affected by the contrast material of the chest CT scan.

For patients with non-iodine-avid disease, the detection of metastases may be delayed. Furthermore, it has been reported that stimulated serum Tg determinations most sensitively detect recurrence and metastasis. However, it should also be noted that even an undetectable stimulated Tg with negative Tg Ab, as in the present cases, does not exclude a metastatic focus.

Although more recent publications have provided data that support the use of FDG-PET scanning for indications beyond simple disease localization in Tg-positive, radioactive iodine scan-negative patients, the clinical application of FDG-PET in patients with thyroid cancer with stimulated Tg negative and radioactive iodine scan-negative are not recommended routinely. However, patients with cancer can receive medical costs benefits through the National

Figure 1 The F-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (CT) scan (A: axial view, B: coronal view) shows a focal increased FDG uptake lesion (maximum standardized uptake value, SUVmax = 6.5) (A, B). Chest CT scan shows an enhancing nodule measuring 1.3cm in the anterobasal segment of the right lower lobe (arrow) (C).
Cancer Registration in Korea and costs of radiologic imaging studies are not expensive. Therefore, the use of FDG-PET-CT is rapidly increasing in real clinical practice in Korea. Wang et al. reported a sensitivity of 79.3% for PET in patients with a negative iodine scan, compared with only 18.6% sensitivity in those with positive iodine scan [10]. In the two presented cases, the pulmonary nodule in each patient was detected by chance. If we had not performed FDG-PET, detection of these nodules may have been delayed until other clinical clues developed.

The cause of a single metastasis in PTC is unknown. Although the mechanism is unclear, macronodular single metastatic foci and loss of capability in the uptake of radioiodine (functional loss of iodine uptake) is responsible for an evident worsening in prognosis.

However, as highlighted by the second case, pulmonary nodules in patients who have PTC can be primary lung cancer. Although the results of $^{131}$I WBS and serum Tg were negative, several nodules of lung were thought initially to represent a metastatic PTC due to a typical finding for metastasis of PTC. However, pulmonary nodular lesions were identified as pulmonary adenocarcinoma through PTNB and TBLB. In general, because primary lung cancer carries a poorer prognosis than PTC, if physicians consider multiple lung nodules...
as metastatic PTC, then inappropriate treatment may worsen prognosis.

The accurate diagnosis of a pulmonary nodule in patients with PTC is important in the choice of the optimal treatment. Radioactive iodine has been the mainstay of treatment for patients with distant metastases; young patients having iodine-avid pulmonary micrometastases achieved remission rates of 90% at 10 years [1]. However, for patients with metastatic disease for which the ability to take up radioactive iodine is lost, survival is poor (5-year and 10-year survival rate of 29% and 10%, respectively) [11]. A study by Casara et al. reported that the oldest patients (mean age 61.9 years) showed a tendency of nonfunctioning and macronodule metastasis. For patients with pulmonary metastases that are large or nonresponsive to radioactive iodine, surgical resection can be considered [11].

The challenging issue in differentiated thyroid cancer is that there are patients with metastatic disease who can lose their radioiodine uptake and have negative stimulated serum Tg. A pulmonary nodule detected by FDG-PET in patients with PTC even showing negative for both stimulated serum Tg and $^{131}$I WBS includes a considerable variety of entities. Thus, a diagnosis must be made with caution.

**Conclusions**

The present cases were considered to offer important information that physicians should be cautious and make efforts for an accurate diagnosis about pulmonary nodules on FDG-PET-CT in patients who have PTC with no evidence of metastasis such as negative $^{131}$I WBS and undetectable stimulated serum Tg levels.

**Abbreviations**

Ab: Antibody; CK: Cytokeratin; FDG-PET-CT: F-18 fluorodeoxyglucose positron emission tomography-computed tomography; PTC: Papillary thyroid carcinoma; PTNB: Percutaneous transthoracic needle biopsy; RLL: Right lower lobe; TBLB: Transbronchial lung biopsy; Tg: Thyroglobulin; TTF-1: Thyroid transcription factor-1; WBS: Whole body scan.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

CHJ and JOM contributed to patients’ diagnosis and treatment. HJG and BYK participated in the literature review. JMP and HSH contributed to radiology-related issues and JJK contributed to histology-related issues. CHK and SKK participated in interpretation of the case. All authors read and approved the manuscript.

**Consent**

Written informed consents were obtained from the two patients for publication of these case reports and any accompanying images. A copy of the written consents is available for review by the Editor-in-Chief of this journal.

**Author details**

1. Department of Internal Medicine, Division of Endocrinology and Metabolism, Soonchunhyang University School of Medicine, Bucheon, Korea.
2. Department of Nuclear medicine, Soonchunhyang University School of Medicine, Bucheon, Korea.
3. Department of Pathology, Soonchunhyang University School of Medicine, Bucheon, Korea.
4. Department of Radiology, Soonchunhyang University School of Medicine, Bucheon, Korea.
5. Division of Endocrinology and Metabolism, Soonchunhyang University School of Medicine, #108 Jung-Dong, Wonmi-Ku, Bucheon, Kyunggi-Do 110-746, Korea.

Received: 3 April 2012 Accepted: 29 August 2012
Published: 31 October 2012
References

1. Durante C, Haddy N, Baudin E, Leboulleux S, Harti D, Travaqli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M: Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006, 91:2893–2899.

2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, Mciiver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167–1214.

3. Chung JK, So Y, Lee JS, Choi CW, Lim SW, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY: Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999, 40:986–992.

4. Choi MY, Chung JK, Lee HY, So Y, Park DJ, Jeong JM, Lee DS, Lee MC, Cho BY: The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 131I whole body scan: a single-center study of 108 patients. Ann Nucl Med 2006, 20:547–552.

5. Westbury C, Vini L, Fisher C, Harmer C: Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin. Thyroid 2000, 10:171–176.

6. Worm AM, Holten I, Tanning E: Nuclear imaging of pulmonary metastases in thyroid carcinoma. Acta Radiol Oncol 1980, 19:401–403.

7. Lee JH, Ahn SJ, Kim HS, Jang SE, Koh JS, Lee YY, Kim CH, Lee JC: Solitary pulmonary metastasis of a thyroid papillary microcarcinoma, masquerading as primary lung cancer. Endocrinol Metab 2011, 26:78–83.

8. Shigematsu H, Andou A, Teramoto A, Matsuo K, Oda W, Yamasaki A, Higashi R: Solitary lung metastasis diagnosed 30 years after surgery for thyroid cancer. Ann Thorac Surg 2009, 88:2016–2017.

9. Nakada K, Shimahara T, Takei T, Omatsu T, Kamishima T, Onodera Y, Tamaraki N, Miyasaka K: Non-typical lung nodules in patients with post-surgical differentiated thyroid cancer: Correlation with pathologic findings. J Nucl Med 2006, 47(Suppl 1):S27.

10. Wang H, Fu HL, Li JN, Zhou RJ, Hui Gu Z, Wu JC, Huang G: Comparison of whole-body 18FDG SPECT and posttherapeutic 131I scintigraphy in the detection of metastatic thyroid cancer. Clin Imaging 2008, 32:32–37.

11. Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Grelli ME, Busnardo B: Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993, 34:1626–1631.

doi:10.1186/1752-1947-6-374
Cite this article as: Jung et al.: Lung nodule detected by F-18 fluorodeoxyglucose positron emission tomography-computed tomography in patients with papillary thyroid cancer, negative 131I whole body scan, and undetectable serum-stimulated thyroglobulin levels: two case reports. Journal of Medical Case Reports 2012 6:374.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit